- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01851070
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
New South Wales
-
Camperdown, New South Wales, Austrália, 2050
- Royal Prince Alfred Hospital
-
-
Tasmania
-
Hobart, Tasmania, Austrália, 7000
- Southern Clinical Research Pty Ltd
-
-
Victoria
-
Malvern, Victoria, Austrália, 3145
- Emeritus Research
-
-
-
-
Alabama
-
Anniston, Alabama, Estados Unidos, 36207
- Pinnacle Research Group
-
-
Arizona
-
Gilbert, Arizona, Estados Unidos, 85234
- Arthrocare Arthritis Care and Research PC
-
-
California
-
El Cajon, California, Estados Unidos, 92020
- TriWest Research Associates
-
Los Angeles, California, Estados Unidos, 90025
- UCLA
-
Upland, California, Estados Unidos, 91786
- Inland Rheumatology Clinical Trials Incorporated
-
-
Florida
-
Ocala, Florida, Estados Unidos, 34474
- Ocala Rheumatology Research Center
-
Palm Harbor, Florida, Estados Unidos, 34684
- Arthritis Center
-
Sarasota, Florida, Estados Unidos, 34239
- Sarasota Arthritis Research Center
-
Tampa, Florida, Estados Unidos, 33614
- McIlwain Medical Group
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21224
- JHU Arthritis Center Baltimore
-
Frederick, Maryland, Estados Unidos, 21702
- Arthritis Treatment Center
-
-
Massachusetts
-
Worcester, Massachusetts, Estados Unidos, 01605
- Reliant Medical Group
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Mayo Clinic
-
-
New Jersey
-
Fair Lawn, New Jersey, Estados Unidos, 07410
- Office of Ramesh C. Gupta, MD
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28210
- DJL Clinical Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73102
- Health Research of Oklahoma
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15261
- University of Pittsburgh
-
-
Tennessee
-
Jackson, Tennessee, Estados Unidos, 38305
- West Tennessee Research Institute
-
-
Texas
-
Houston, Texas, Estados Unidos, 77034
- Accurate Clinical Research
-
San Antonio, Texas, Estados Unidos, 78217
- Texas Arthritis Research Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Males and Females ages 18-80 years old
- Active rheumatoid arthritis (RA) disease as per 2010 ACR/EULAR classification criteria for the diagnosis of RA.
- Must be positive for rheumatoid factor and/or anti-cyclic citrullinated peptide (anti-CCP3) but without extra-articular disease or functional limitation
Patient with active RA defined as:
- ≥ 4 tender joint count (TJC) 28 joint count at screening and
- ≥ 4 swollen joint count (SJC) count 28 joint count at screening
- ESR ≥ 28 mm/hr or hsCRP >2.0 mg/L
- Patient has been taking MTX for at least 4 months with dose and route of administration stable for at least 8 weeks prior to screening
- Patient has had an inadequate response to at least one TNFα inhibitor with last dose at least 6 weeks prior to screening
- Use of oral DMARD (sulfasalazine, hydroxychloroquine, chloroquine and leflunomide) is permitted but must be stable for at least 3 months prior to screening
Exclusion Criteria:
- Pregnant women or women who are breastfeeding.
- Other investigational therapy received within 8 weeks or five half-lives (whichever is longer) prior to Screening (except as in exclusion #13).
- Known or suspected alcohol or drug abuse within three years preceding Screening.
- Autoimmune disease other than RA (such as systemic lupus erythematosus (SLE), mixed connective tissue disease, scleroderma, polymyositis/dermatomyositis, vasculitis)
- History of or current inflammatory joint disease other than RA (such as tophaceous gout, reactive arthritis, psoriatic arthritis, ankylosing spondylitis or other spondyloarthropathy, Lyme disease). Patients primarily diagnosed with osteoarthritis are excluded.
- Bedridden or confined to a wheelchair or patients with > 3 arthroplasties due to RA.
- History of diagnosed and/or treated malignancy with no evidence of recurrence in past 5 years
- Surgical procedures planned to occur during the trial (these patients may be rescreened following completion of and recovery from the surgical procedure).
- Use of TNFα inhibitor for treatment of RA at time of screening or within the 6 weeks prior to screening.
- Prior use of biologic agent for treatment of RA within 6 weeks prior to screening
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Comparador de Placebo: Normal Saline Placebo
Placebo will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.
|
|
Comparador Ativo: Allogeneic Mesenchymal Precursor Cells
Mesenchymal Precursor Cells (MPCs), either 1.0 or 2.0 million cells/kg, will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Evaluation of the safety of a single IV infusion of allogeneic MPCs compared to placebo at 12 weeks post-infusion
Prazo: 12 weeks post IV Infusion
|
To evaluate the safety, tolerability and feasibility of a single intravenous (IV) infusion of allogeneic mesenchymal precursor cells (MPCs) compared to placebo at 12 weeks post-infusion in the treatment of patients with active rheumatoid arthritis (RA) who have received methotrexate +/- other oral DMARDs for at least 4 months and who have had an incomplete response to at least one course of a TNFα inhibitor. Overall safety will be based on the overall assessment of AE/SAEs, Vital Signs, Physical Examination, clinical laboratory tests, ECGs and Chest x-ray. |
12 weeks post IV Infusion
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Evaluation of the efficacy of a single intravenous infusion of allogeneic MPCs compared with placebo at 12 weeks post-infusion with MPCs or placebo in the treatment of patients with active RA
Prazo: 12 weeks post IV infusion with MPCs
|
To assess the efficacy of a single intravenous infusion of allogeneic MPCs compared with placebo at 12 weeks post-infusion with MPCs or placebo in the treatment of patients with active RA who have received methotrexate +/- other DMARDs for at least 4 months and who have had an incomplete response to least one TNFα inhibitor.
|
12 weeks post IV infusion with MPCs
|
Evaluation of long-term safety and efficacy of a singly IV infusion of allogeneic MPCs in patients with active RA
Prazo: 52 weeks post IV Infusion
|
To evaluate the long-term efficacy and safety of allogeneic MPCs over the entire study duration in the treatment of patients with active RA who have received methotrexate +/- other DMARDs for at least 4 months and who have had an incomplete response to at least one TNFα inhibitor Safety will be assessed according to the following:
Efficacy will be assessed according to the following:
|
52 weeks post IV Infusion
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- MSB-RA001
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Solução salina normal
-
Helsinki University Central HospitalLaerdal Foundation; The Finnish Medical Association; Orion Research Foundation; Finnish...ConcluídoParada Cardíaca Fora do HospitalDinamarca, Finlândia
-
Columbia UniversityNational Heart, Lung, and Blood Institute (NHLBI)ConcluídoObesidade | Doença cardiovascular | Diabetes Mellitus, Tipo IIEstados Unidos
-
Texas Cardiac Arrhythmia Research FoundationSuspensoArritmia VentricularEstados Unidos
-
Ann & Robert H Lurie Children's Hospital of ChicagoRetirado
-
Texas Cardiac Arrhythmia Research FoundationConcluído
-
MemorialCare Health SystemConcluídoDuração do Trabalho | Segunda fase do trabalho de parto | Hidratação Intravenosa do Trabalho de PartoEstados Unidos
-
Kangbuk Samsung HospitalConcluído
-
University of MichiganRadiological Society of North AmericaRescindido
-
University of HaifaWestern Galilee Hospital-NahariyaRecrutamento
-
Virginia Commonwealth UniversityUnited States Department of DefenseRetirado